Adaptimmune Therapeutics plc has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group, to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.   The collaboration entails the development of allogeneic T-cell therapies for up to five shared cancer targets, and development of personalized allogeneic T-cell therapies.   Adaptimmune will be responsible for developing clinical candidates using its induced p...